Economic Analysis of Health Care Interventions

Seminars in Radiation Oncology

Volumn 18, Issue 3, 2008, Pages 168-174

  Konski, Andre ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ECONOMIC ASPECT; GOVERNMENT; HEALTH CARE COST; HEALTH INSURANCE; MEDICAID; MEDICARE; PRIORITY JOURNAL; UNITED STATES;

CLINICAL TRIALS AS TOPIC; DECISION SUPPORT TECHNIQUES; HEALTH EXPENDITURES; HUMANS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 44149102415     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2008.01.004     Document Type: Article

References (28)

1. Drummond M. Australian guidelines for cost-effectiveness studies of pharmaceuticals: The thin end of the boomerang?. Pharmacoeconomics 1 (1992) 61-69
2. Drummond M.F. Basing prescription drug payment on economic analysis: The case of Australia. Health Aff (Millwood) 11 (1992) 191-196
3. Drummond M.F., and Mason A.R. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol 25 (2007) 191-195
4. Colmenero F., Sullivan S.D., Palmer J.A., et al. Quality of clinical and economic evidence in dossier formulary submissions. Am J Manag Care 13 (2007) 401-407
5. Drummond M., Stoddart G.L., and Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes (1995), Oxford University Press, Oxford
6. Lipscomb J.W., and Torrance G.W. Time preference. In: Gold M.R., Siegel J.E., Russell L.B., et al. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York 214-235
7. Luce B.R., Manning W.G., Siegel J.E., et al. Estimating costs in cost-effectiveness analysis. In: Gold M.R., Siegel J.E., and Russell L.B. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York 176-213
8. Nord E. EuroQol: Health-related quality of life measurement. Valuations of health states by the general public in Norway. Health Policy 18 (1991) 25-36
9. Boyle M.H., Furlong W., Feeny D., et al. Reliability of the Health Utilities Index-Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Qual Life Res 4 (1995) 249-257
10. EuroQol-A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16 (1990) 199-208
11. Ubel P.A., Hirth R.A., Chernew M.E., et al. What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med 163 (2003) 1637-1641
12. Neymark N., Adriaenssen I., Gorlia T., et al. Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 11 (2002) 233-248
13. O'Sullivan A.K., Thompson D., and Drummond M.F. Collection of health-economic data alongside clinical trials: Is there a future for piggyback evaluations?. Value Health 8 (2005) 67-79
14. Drummond M.F., and Davies L. Economic analysis alongside clinical trials.Revisiting the methodological issues. Int J Technol Assess Health Care 7 (1991) 561-573
15. Willan A.R., and O'Brien B.J. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ 8 (1999) 203-211
16. Sonnenberg F.A., and Beck J.R. Markov Models in medical decision making: A practical guide. Med Decis Making 13 (1993) 322-338
17. Beck J.R., and Pauker S.G. The Markov process in medical prognosis. Med Decis Making 3 (1983) 419-458
18. Naimark D., Krahn M.D., Naglie G., et al. Primer on medical decision analysis: Part 5-Working with Markov processes. Med Decis Making 17 (1997) 152-159
19. Karnon J., Delea T., and Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: The UK perspective. Eur J Health Econ (2007) [Epub ahead of print]
20. Schousboe J.T., Taylor B.C., Fink H.A., et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 298 (2007) 629-637
21. Coupe V.M., Berkhof J., Verheijen R.H., et al. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG 114 (2007) 416-424
22. Delea T.E., Karnon J., Sofrygin O., et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 7 (2007) 608-618
23. Konski A., Sherman E., Krahn M., et al. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int J Radiat Oncol Biol Phys 63 (2005) 788-794
24. Fleming C., Wasson J.H., Albertsen P.C., et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 269 (1993) 2650-2658
25. Hummel S., Paisley S., Morgan A., et al. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: A systematic review. Health Technol Assess 7 ix-x (2003) 1-157 iii
26. Konski A., Watkins-Bruner D., Brereton H., et al. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma. Cancer 106 (2006) 51-57
27. Konski A., Watkins-Bruner D., Feigenberg S., et al. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 408-415
28. Konski A., Speier W., Hanlon A., et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol 25 (2007) 3603-3608